Effects of Dapagliflozin on Heart Health in Patients with Acute Coronary Syndromes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the potential benefits of dapagliflozin, a medication typically used for type 2 diabetes, in patients who have experienced an acute myocardial infarction. The study is designed as a prospective, randomized, double-blind, placebo-controlled trial, where participants will receive either dapagliflozin or a placebo within seven days of their heart attack. The primary focus is to assess platelet aggregation and other cardiovascular biomarkers to determine if dapagliflozin has effects beyond glycemic control. Additional exploratory analyses will investigate various cardiac and metabolic parameters over a specified follow-up period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men and women aged ≥ 18 years (women of childbearing age must have a negative pregnancy test);
* In routine use of dual antiplatelet therapy with ASA plus an ADP receptor antagonist, according to institutional routines;
* Acute myocardial infarction, with or without ST-segment elevation (STEMI/NSTEMI) defined according to the 4th Universal Definition of Acute Myocardial Infarction, with up to 7 days of evolution from the onset of symptoms;
* Signature of the Free and Informed Consent Term.

Exclusion criteria:

* Current or recent (within 24 months) treatment with pioglitazone and/or use of pioglitazone for a total of 2 years or more during a lifetime at any time;
* Current or recent (within 12 months) treatment with rosiglitazone;
* Chronic use (\>15 consecutive days) of any SGLT2 inhibitor at the time of hospitalization;
* Chronic use (\>30 consecutive days) with an oral steroid at a dose equivalent to prednisolone ≥10 mg (eg, betamethasone ≥1.2 mg, dexamethasone ≥1.5 mg, hydrocortisone ≥40 mg) per day;
* Systolic BP \> 180 or diastolic BP \> 100 mmHg at randomization;
* Diagnosis of Type 1 diabetes mellitus, MODY (maturity onset diabetes of the Young) or diabetes mellitus secondary to diverse endocrinopathy, pancreatic resection, medication, pancreas neoplasia or chronic pancreatitis;
* History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time;
* History of any other malignancy within 5 years (with the exception of skin cancers successfully treated non-melanoma);
* Chronic cystitis and/or recurrent urinary tract infections (3 or more in the last year);
* Any condition that, in the opinion of the Investigator, may render the research participant unfit to complete the study, including, but not limited to, cardiovascular disease (KILLIP \> 2, modified Forester \> IIa,35 recurrent ventricular arrhythmias) or non cardiovascular (eg, active malignancy other than basal cell carcinoma, cirrhosis, chronic lung disease, severe autoimmune disease);
* Pregnancy or lactation;
* Active participation in another clinical trial
* Patients with septic shock or severe glycemic decompensation requiring the use of IV insulin at the time of randomization;
* TGP/ALT(Alanine Amino Transferase) \>3x the upper limit of normality (ULN) or total bilirubin \>2.5 x ULN;
* Estimated glomerular filtration rate (GFR) \< 45 ml/min/1.73m² , calculated by MDRD, or kidney transplant;
* Known thrombophilias or thrombocytosis;
* Blood dyscrasias or any disorder that causes hemolysis, previously known;
* Hematological abnormality (Hb ≤ 11g/dL or \> 17g/dL, leukocytes ≤ 4500/mm³ or \>11000/mm³, platelet count \<150,000/mm³ or \> 450,000/mm³)

Where it's running

• Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo
  São Paulo, São Paulo, Brazil Recruiting

Study contacts

• Study coordinator: Jose JN Nicolau
• Email: jose.nicolau@incor.usp.br
• Phone: +55 (11) 2661-5058

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding sex hormones and inflammation in heart disease

  This study looks at how sex hormones and inflammation affect heart disease in women to better understand their unique risks and improve treatment.

  Recruiting Queen Mary University of London · London · NCT06327984

• Using magnetocardiography to identify heart attacks

  This study is testing if a new noninvasive heart scan method can help doctors better identify heart attacks in people with chest pain and healthy volunteers.

  Recruiting Qilu Hospital of Shandong University · Jinan, Shandong · NCT05896826

• Investigating risk factors in patients with acute coronary syndrome undergoing a procedure

  This study is trying to find out what risk factors affect patients with acute coronary syndrome who are having a heart procedure and how these factors relate to their health outcomes over two years.

  Recruiting Jinan Central Hospital · Jinan, Shandong · NCT05719545

• Assessing heart disease risk using carotid ultrasound and stress tests

  This study is testing if combining a special ultrasound of the neck with stress tests can better identify people at risk for serious heart problems over the next three years.

  Recruiting at 5 sites Queen's University · Calgary, Alberta and 5 other locations · NCT05416385

• Registry collecting data on patients undergoing heart artery procedures

  This study is collecting information from patients who are having heart artery procedures to see how they do during and after their treatment.

  Recruiting Federico II University · Naples · NCT05248165

• Optimal antithrombotic strategy for patients with atrial fibrillation undergoing PCI

  This study is testing whether a new blood-thinning treatment for patients with atrial fibrillation undergoing heart procedures is safer and just as effective as the traditional approach that includes more medications.

  Recruiting at 18 sites Phase 4 St. Antonius Hospital · Aalst and 19 other locations · NCT04436978

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.